Description
RIPEX 225 is an oily injection solution containing three short-acting anabolics: Testosterone Propionate, Masteron Propionate, and Trenbolone Acetate, at 75mg/ml each for a total concentration of 225mg per ml. All three compounds have short half-lives (1-3 days), enabling synchronized injection frequencies.
Per study reports RIPEX 225 delivers the classical pre-contest profile: sharp on/off, rapid flood-in, fast mid-protocol adjustability. Compared to Blend 500 with enanthate esters, RIPEX is substantially more agile - cycle adjustments take effect in 1-2 weeks instead of 3-4 weeks.
Pharmacology combines the three compound profiles: Test as androgenic base, Masteron for dry hardness and anti-estrogen action, Trenbolone for sharp androgenic potency without aromatization. Water retention stays low thanks to the Masteron portion and low test conversion rate at moderate doses.
In practice RIPEX 225 requires injections every 1-2 days for stable plasma levels. This makes the stack burdensome in long cycles but ideal for pre-contest research phases (4-8 weeks before competition).
Known effects are the sum of individual compounds: Tren-typical night sweats, sleep disturbances, aggression; Masteron-typical hardness; Test-typical mild estrogen effects. Frequent injections can elevate injection-site stress.
You can order RIPEX 225 as an oily injection solution in 10-pack at 225mg/ml.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
RIPEX 225 combines three short-acting anabolics - the risk profile described in the literature is the sum of the individual compounds, and the frequent injections additionally increase strain on the injection sites.
Documented in studies and the application literature:
- Trenbolone portion: as a 19-nor compound with progestagenic residual action, elevated prolactin levels, night sweats, sleep disturbances and aggression are documented. Trenbolone does not aromatize.
- Test portion: the testosterone portion aromatizes to estradiol, with documented mild estrogen effects such as water retention, mitigated by the Masteron portion.
- Suppression of endogenous production: all three compounds throttle the body’s own testosterone production via the HPTA axis. Testicular atrophy and reduced fertility are documented.
- Cardiovascular: the literature describes unfavorable shifts in the lipid profile (HDL falls), elevated hematocrit and an associated thrombosis risk.
- Other: acne, accelerated hair loss with genetic predisposition, injection-site irritation from the every-1-2-days application.
Baseline bloodwork before, during and after a research protocol is strongly advised. This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Comparative pharmacokinetics of testosterone esters - Testosterone (Springer) 1998, Behre & Nieschlag: comparison of pharmacokinetics of testosterone esters including propionate.
- The Effects of Supraphysiologic Doses of Testosterone on Muscle Size and Strength in Normal Men - NEJM 1996, Bhasin et al: classical dose-response study on testosterone effects on muscle mass and strength.
- 17β-Hydroxyestra-4,9,11-trien-3-one (trenbolone) exhibits tissue selective anabolic activity: effects on muscle, bone, adiposity, hemoglobin, and prostate - Am J Physiol Endocrinol Metab 2011, Yarrow et al: tissue-selective anabolic action of trenbolone.
- A dose-response evaluation of androgens in the treatment of metastatic breast cancer - Cancer 1973, Talley et al: controlled study on dromostanolone (Masteron) in metastatic breast cancer.
- Cardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid Use - Circulation 2017, Baggish et al: cohort study on cardiovascular effects of chronic AAS use.
